Regencell Bioscience (NASDAQ:RGC) Stock Price Down 15.1% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price fell 15.1% on Wednesday . The company traded as low as $10.17 and last traded at $9.41. 83,300 shares were traded during trading, a decline of 70% from the average daily volume of 279,030 shares. The stock had previously closed at $11.08.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience currently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

The firm has a 50 day simple moving average of $24.53 and a two-hundred day simple moving average of $25.79.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

Large investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in Regencell Bioscience during the second quarter worth about $1,701,000. BNP Paribas Financial Markets bought a new position in shares of Regencell Bioscience in the second quarter worth about $768,000. XTX Topco Ltd acquired a new stake in shares of Regencell Bioscience in the 3rd quarter valued at approximately $598,000. Hudson Bay Capital Management LP acquired a new stake in shares of Regencell Bioscience in the 4th quarter valued at approximately $275,000. Finally, Vident Advisory LLC grew its holdings in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the last quarter. 0.13% of the stock is owned by institutional investors and hedge funds.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.